Cue Biopharma Files 8-K on Shareholder Votes and Financials
Ticker: CUE · Form: 8-K · Filed: Oct 8, 2024 · CIK: 1645460
Sentiment: neutral
Topics: procedural, financials, corporate-actions
TL;DR
Cue Biopharma filed an 8-K for shareholder votes & financials.
AI Summary
On October 8, 2024, Cue Biopharma, Inc. filed an 8-K report. The filing indicates that the company is submitting matters to a vote of its security holders and also includes financial statements and exhibits. The company was formerly known as Imagen Biopharma, Inc. and changed its name on June 17, 2015.
Why It Matters
This filing informs investors about upcoming shareholder votes and provides access to the company's latest financial statements and exhibits, which are crucial for evaluating the company's performance and future prospects.
Risk Assessment
Risk Level: low — This is a routine filing that primarily concerns procedural matters and financial reporting, with no immediate indication of significant operational or financial distress.
Key Players & Entities
- Cue Biopharma, Inc. (company) — Registrant
- Imagen Biopharma, Inc. (company) — Former company name
- October 8, 2024 (date) — Date of report
- June 17, 2015 (date) — Date of name change
- 40 Guest Street Boston, Massachusetts 02135 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for Cue Biopharma, Inc.?
The primary purpose is to report on the submission of matters to a vote of security holders and to include financial statements and exhibits.
When was the report filed by Cue Biopharma, Inc.?
The report was filed on October 8, 2024.
What was Cue Biopharma, Inc.'s former name?
Cue Biopharma, Inc.'s former name was Imagen Biopharma, Inc.
On what date did the company change its name from Imagen Biopharma, Inc.?
The company changed its name on June 17, 2015.
Where are Cue Biopharma, Inc.'s principal executive offices located?
Cue Biopharma, Inc.'s principal executive offices are located at 40 Guest Street, Boston, Massachusetts 02135.
Filing Stats: 744 words · 3 min read · ~2 pages · Grade level 12 · Accepted 2024-10-08 16:00:08
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share CUE Nasdaq Capital Market
Filing Documents
- cue-20241008.htm (8-K) — 61KB
- cue-ex3_1.htm (EX-3.1) — 13KB
- 0000950170-24-113520.txt ( ) — 215KB
- cue-20241008.xsd (EX-101.SCH) — 45KB
- cue-20241008_htm.xml (XML) — 5KB
03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On October 8, 2024, Cue Biopharma, Inc. (the "Company") filed a Certificate of Amendment (the "Certificate of Amendment") to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware effecting an amendment to increase the number of authorized shares of the Company's capital stock from 110,000,000 to 210,000,000 and increase the number of authorized shares of the Company's common stock from 100,000,000 to 200,000,000. The Certificate of Amendment was approved by the Company's stockholders at the Special Meeting (as defined below). The foregoing description of the Certificate of Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Certificate of Amendment, a copy of which is filed herewith as Exhibit 3.1 and incorporated herein by reference.
07. Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders. The Company held a Special Meeting of Stockholders (the "Special Meeting") on October 8, 2024. The certified results of the matters voted upon at the Special Meeting, which are more fully described in the Company's Proxy Statement for the Special Meeting as filed with the Securities and Exchange Commission on September 10, 2024, are as follows (where applicable, voting results reflect fractional shares rounded down to the nearest whole share): 1. The Company's stockholders approved the Certificate of Amendment to increase the number of authorized shares of the Company's capital stock from 110,000,000 to 210,000,000 and increase the number of authorized shares of the Company's common stock from 100,000,000 to 200,000,000 ("Proposal 1"), with votes cast as follows: For Against Abstain 29,291,818 7,409,258 499,006 2. The Company's stockholders approved the proposal to adjourn the Special Meeting to a later date or dates, if necessary, to permit further solicitation of proxies in the event that there are insufficient votes for the adoption and approval of Proposal 1, but adjournment of the Special Meeting was unnecessary because there was a quorum present and there were sufficient votes received at the time of the Special Meeting to Proposal 1.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 3.1 Certificate of Amendment to the Company's Amended and Restated Certificate of Incorporation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Cue Biopharma, Inc. Date: October 8, 2024 By: /s/ Daniel R. Passeri Name: Daniel R. Passeri Title: Chief Executive Officer